RxDoctor Payments Data

Bryan Abernathy, MD

Family Medicine · Fayetteville, ARNPI 1649218892

Payments from drug & device makers

$334in general payments, 2019–2025

Across 9 payments — averaging $37.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$117
  • Medtronic$117
  • Supernus Pharmaceuticals, Inc.$32
  • Abbott$17
  • AbbVie$14
  • Pfizer$13
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$334 in reported general payments places this provider in the 40th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$79,715
Medicare patients
138
Services billed
8,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$62,507
MounjaroTirzepatide35$36,193
EntrestoSacubitril/Valsartan13$22,411
FarxigaDapagliflozin Propanediol29$19,136
EliquisApixaban16$16,228
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,581
Breo ElliptaFluticasone/Vilanterol24$12,098
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,818
MyrbetriqMirabegron12$5,545
TrintellixVortioxetine Hydrobromide11$5,040
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$4,523
SynthroidLevothyroxine Sodium77$4,391
Omeprazole125$2,302
Gabapentin144$2,219
Rosuvastatin Calcium209$2,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$16,22816 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$12$5,04011 claims
AbbVieSynthroid$14$4,39177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →